Introduction
Glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors because of its rapid cell growth and immunosuppressive capabilities. Because of the ineffectiveness of many chemotherapy agents and drug treatments, immune therapeutic strategies are an appealing approach; however, they are limited by the profound immune suppression that these tumors mediate. Increased antitumor immune responses have been linked to enhanced survival in many cancers, including GBM (1-7). Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is a potent regulator of tumorigenesis and immune suppression (8, 9) . STAT3 is upregulated in many cancers, including gliomas (10) and promotes tumorigenesis by preventing apoptosis and enhancing proliferation, angiogenesis, invasion, and metastasis (11, 12) . The STAT3 pathway can also become active in tumor-infiltrating immune cells, markedly impairing their antitumor effector responses (9) while enhancing the functional activity of immune-suppressive cells (13, 14) .
Glioma cancer stem cells (gCSCs) demonstrate activation of the STAT3 pathway (12) , which has been shown to modulate their profound immune-suppressive properties (13, 14) .
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miR-124 transfection in gCSCs, astrocytes and T-cells
The precursor form of miR-124 (30 nM) and the scramble negative control were used to transfect gCSCs and T-cells using the siPORT NeoFX transfection agent (Applied Biosystems) or Nucleofector transfection kit (Lonza, Allendale, NJ). Cells were incubated for 72 hours at 37°C to determine cell surface marker expression and collect secreted cytokines. miR-124 expression was verified via RT-PCR after transfection. The morphologic characteristics of the gCSCs were documented at 48 hours after the transfection. A rescue experiment of miR-124 inhibition was accomplished by cotransfection with a plasmid expressing wild-type, constitutively active STAT3 without a miR-124 binding 3' UTR site (kindly provided by Dr. Jinbo Yang).
In vivo experiments
The miR-124 duplex that mimics pre-miR-124a (sense: 5'-UAAGGCACGCGGUGAAUGCCA-3', antisense: 3'-UAAUUCCGUGCGCCACUUACG-5') and the scramble control miRNA duplex (sense: 5'-AGUACUGCUUACGAUACGGTT-3', antisense:
3'-TTUCAUGACGAAUGCUAUGCC-5') were synthesized (SynGen, San Carlos, CA). The sequence of murine miR-124 is identical to human miR-124 on the basis of NCBI blast data (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The treatment cohorts consisted of 20 µg of the miR-124 duplex or scramble control in 10 µL of PBS mixed with the vehicle (80 µL PBS containing 10 µL engineered murine glioma models.
Statistical analysis
The distribution of each continuous variable was summarized by its mean, standard deviation, and range. The distribution of each categorical variable was summarized in terms of its frequencies and percentages. Continuous variables were compared between treatment groups by a two-sample t test. In the case of comparing two paired groups, a paired t test is conducted. Kaplan-Meier curves were used to estimate unadjusted time to event variables. Logrank tests were used to compare each time-to-event variable between groups. P values of less than 0.05 (two-sided) were considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences v.12.0.0 (SPSS, Chicago, IL) and SAS v. 9.1 (SAS Institute, Cary, NC). Error bars represent SD.
Results

miR-124 expression in gliomas
To determine the pattern of miR expression in GBM relative to normal brain tissue, we used the Human miRNA OneArray Microarray v2. miR-124 emerged as a leading candidate, with a mean 24.6-fold decrease in expression from that seen in normal brain tissue (Supplementary Table 1) . A subsequent analysis using reverse transcription-polymerase chain reaction (RT-PCR) confirmed that miR-124 was absent or minimally expressed in GBM specimens (n = 4), glioma cell lines (n = 2), and gCSCs (n = 4) compared with normal brain tissues (n = 3) (Fig. 1A) . GBM-associated microglia/macrophages also have low or undetectable expression of miR-124 (Supplementary Fig. 1 ). When the gCSCs were placed under neural differentiation conditions, miR-124 expression levels were increased (Supplementary Fig. 1 ). Because miR-124 was a leading candidate down regulated in GBM, as observed by ourselves and others (27, 31) , we determined whether it was decreased in other 
miR-124 interacts with the STAT3 pathway
To determine which miRs interact with STAT3, we used TargetScan to identify a group of miRs with conserved target sites in the STAT3 3'-UTR. Theoretically, these miRs can inhibit STAT3 expression and thus down regulate STAT3-mediated immune suppression in GBM. The top-rated candidates were miR-124, miR-17, miR-125, and miR-129, with aggregate P CT scores of 0.85, 0.85, 0.84, and 0.58 (respectively) (Supplementary Table 2 ). An additional analysis suggests that miR-124 is predicted to bind to STAT3 (http://cbcsrv.watson.ibm.com:8080/teriresias/RNA22). Therefore, on the basis of these cumulative bioinformatics data, we performed a mechanistic and therapeutic evaluation of miR-124. Because the predicted binding sites of miR-124 to STAT3 are in a conserved, homologous region ( Fig. 1C) , we determined whether miR-124 directly inhibits STAT3 protein expression by binding to the 3'-UTR. miR-124-negative HeLa cells were transfected with pre-miR-124 plasmid or pre-miR-control plasmid. The 3'-UTR reporter activities of STAT3 were assessed by luciferase assays. miR-124 inhibited STAT3 luciferase activity in cotransfected HeLa cells (Fig.   1D ), whereas directed mutational alteration of the miR-124 3'-UTR STAT3 binding site (Fig. 1C) resulted in complete abolishment of miR-124 inhibition of luciferase activity in cotransfected HeLa cells (Fig. 1D) . Subsequently, both STAT3 and pSTAT3 expression at the protein level were inhibited by miR-124 within gCSCs as detected by Western blot (Fig. 1E) .
In addition to STAT3, TargetScan and other online software also suggest that miR-124 maytarget other components of the STAT3 signaling pathways including IL6Rα, Tyk2, Src Table 3 ). In order to test whether miR-124 suppresses these predicted targets, we investigated the effect of forced expression of miR-124 in five gCSCs isolated from different glioblastoma patients (Fig. 1E) . Shc1 is also a preferred target of miR-124 in gCSCs and is down regulated in all gCSCs treated with miR-124. pMAPK1/3 is down modulated in one gCSC cell line but this line is notable for the lack of IL-6Rα expression, suggesting that p-STAT3 activation may be due to alternative EGFR/MAPK1/3 dominant signaling. Although IL-6Rα, Tyk2, and MAPK1/3 are not preferred targets of miR-124 in gCSCs by Western blot, miR-124 can target at least two key components in the STAT3 signaling pathway (Supplementary Fig. 2 ). To determine if miR-124 can down modulate targets downstream of p-STAT3 such as miR-21, we measured miR-21 level in miR-124 overexpressing gCSCs by RT-PCR and found that miR-21 expression was inhibited by miR-124 (Supplementary Fig. 3 ).
miR-124 reverses gCSC-mediated immune suppression
To determine the phenotypic consequences of up regulating miR-124, we transiently transfected human immune-suppressive gCSCs (13) with precursor miRs and confirmed the up regulation of miR-124 by RT-PCR. The miR-124 expression was increased in the range of 5-20,000 fold among different gCSCs. After 24 hours, gCSCs demonstrated increased adherence to the bottom of the plate, which was more pronounced after 48 hours. Specifically, the typical neurosphere morphology of the gCSCs was altered to become petri dish-attached with an elongated configuration and with contact inhibition (Fig. 2A) . In contrast, transfection of astrocytes with miR-124 did not alter morphology, proliferation, apoptosis or cell cycle status (data not shown). To characterize their immunological phenotype, gCSCs were assessed for their expression of major histocompatibility complex (MHC) I, MHC II, CD40, CD80, CD86, and analyzed the conditioned medium of miR-124-or scramble (control)-transfected gCSCs using enzyme-linked immunosorbent assays (ELISAs) and cytokine and chemokine arrays. Here, we found lower levels of IL-8 (scramble: 5844 ± 1108 pg/ml versus miR-124: 2115 ± 672 pg/ml; n=4, P < 0.05), galectin-3 (scramble: 933 ± 214 pg/ml versus miR-124: 555 ± 72 pg/ml; n=4, P < 0.01), and MIC-1 (scramble: 13 ± 4 pg/ml versus miR-124: 4 ± 1 pg/ml; n=4, P < 0.05) (Supplementary Fig. 1) but not of VEGF. Cytokine and chemokine array data revealed a modest decrease in levels of TGF-β 2 , macrophage migration inhibitory factor, Serpin E1, CX3CL1, CXCL10, CXCL16, and chemokine C-C motif-2, when miR-124 was overexpressed in gCSCs, but these findings were not statistically significant.
To determine whether miR-124 transfection reverses the functional gCSC-mediated immune inhibition of T-cells, we activated with anti-CD3/CD28 naïve CD4+ T-cells from healthy donors' PBMCs in the presence of gCSC medium, 3-day gCSC-conditioned medium from gCSCs transfected with scramble control, miR-124, and miR-124 plus STAT3. The medium from scrambled miRNA-transfected gCSCs inhibited T-cell proliferation by 63.5 ± 13.8% versus 33.0 ± 10.1% in miR-124-transfected gCSCs (n=4, P = 0.023) (Fig. 2B) . Moreover, fewer apoptotic T-cells were induced by medium from miR124-tranfected gCSCs than by medium from scramble-transfected gCSCs (Fig. 2C) . Next, we determined whether miR-124 could diminish forkhead box P3 (FoxP3)+ Treg generation induced from naïve CD4+ T-cells, mediated by gCSC-conditioned medium. Indeed, the medium from miR-124-transfected gCSCs led to decreased FoxP3+ T-cell generation compared with scrambled miRNA-transfected gCSCs (Fig.   2D) . Moreover, these were functional Tregs, as assessed by autologous CD4+ T-cell proliferation in coculture assays (Fig. 2E) . Furthermore, all the effects mediated by miR-124 were reversed by cotransfection of wild-type, constitutively active STAT3 lacking a miR-124 sensitive 3'-UTR fragment (Fig. 2B, C, D, E) . In contrast, miR-21 enhanced gCSC-mediated immune suppression as assessed by suppression of T-cell proliferation (Supplementary Fig.   3 ). 
miR-124 inhibits in vivo glioma growth
Given miR-124's role in modulating the STAT3 pathway and immune responses, we next determined whether miR-124 could exert a therapeutic effect in vivo. To assess the in vivo antitumor efficacy of miR-124, we implanted GL261 murine glioma cells into immune competent C57BL/6 mice and treated them with miR-124 or scramble control (n=10 per group). After the subcutaneous GL261 tumors had grown to a palpable size, miR-124 duplex or scramble control was administered. Subcutaneous tumor growth progressed in all the C57BL/6J mice treated with the scramble control. In contrast, in the miR-124-treated group, the tumor volume was markedly suppressed (P = 0.01) (Fig. 4A) . Gliomas started to shrink as soon as miR-124 was administered; moreover, the tumors continued to regress even after miR-124 treatment was discontinued. In contrast, tumors kept growing aggressively in scramble microRNA-treated and Consistent with the enhanced antitumor activity in the miR-124-treated group, a marked increase in effector cells (i.e., producing IFN-γ or TNF-α) was found in the glioma microenvironment, including CD4+ T-cells ( Fig. 4E ; IFN-γ: from 7.7 ± 2.0% to 21.6 ± 3.3%, P = 0.0032; TNF-α: from 6.4 ± 1.7% to 29.1± 7.4%, P = 0.0066 ) and CD8+ T-cells ( Although we found that miR-124 had a therapeutic effect when injected directly into the tumor, this is unlikely to be a viable therapeutic approach for patients. Therefore, we tested intravenous miR-124 administration in established murine glioma models. Confirming the results of the direct delivery approach, intravenous administration of miR-124 led to marked inhibition of glioma growth in vivo (Fig. 5A) . To determine whether this therapeutic effect was secondarily mediated by the immune system, we implanted GL261 murine glioma cells in immuneincompetent (nude) mice and treated them with miR-124 or scramble control. Intratumoral treatment was initiated when the tumors grew to a palpable size. In the immune-incompetent animal background, miR-124 failed to exert a therapeutic effect, indicating that miR-124 mediates in vivo activity via the immune system (Fig. 5B) .To determine whether treatment with miR-124 was effective against established intracerebral tumors, we administered miR-124 to C57BL/6J mice with intracerebral tumors from GL261 cells, starting after tumor cell implantation.
The median survival duration for the scramble control group was 21.5 days. For mice treated with miR-124, the median survival duration was 32 days (P = 0.02) (Fig. 5C) . When the experiment was repeated in an immune-incompetent model system, therapeutic efficacy was once again lost (Fig. 5D) .
The immune therapeutic efficacy of miR-124 depends on T-cells
To further investigate which T-cell compartment mediates miR-124's in vivo antitumor activity, we depleted CD4+ or CD8+ T-cells in GL261 tumor-bearing mice with neutralizing antibodies while treating those mice with miR-124 or scramble RNA oligonucleotides. We found that depletion of both CD4+ T-cells and CD8+ T-cells completely abrogated the anti-glioma efficacy of miR-124 (Fig. 6A) Fig. 5 ).
After in vivo miR-124 treatment, there is an increase in the miR-124 expression levels in both the peripheral blood T-cells and within the glioma-infiltrating T-cells. This coincided with decreased intracellular p-STAT3 expression (Supplementary Fig. 5 ).
Next, we isolated CD3+ T-cells, transfected them with miR-124 or scramble control, and expanded their numbers in vitro for 48 hours before adoptively transferring these cells into GL261 tumor-bearing mice. This miR-124 transfection inhibited p-STAT3 activity in the adoptively transferred T cells (Fig. 6B) . Consistent with miR-124-enhanced T-cell effector function (as shown in Fig. 3 ) and the miR-124 therapeutic effects relying on T-cells (as shown in 
the CD8+ T-cells within the glioma microenvironment was enhanced (IFN-γ: from 1.4 ± 0.7% to 7.3 ± 1.8%, P = 0.0018; TNF-α: from 5.2 ± 0.8% to 15 ± 4.4%, P = 0.043).
miR-124 modulates T helper cell differentiation
To further investigate whether Th1 and Th17 differentiation are responsive to modulation with miR-124, we activated CD4+CD45RA+CD45RO-naïve T-cells with plate-bound anti-CD3 and soluble anti-CD28 under Th1, Th17, and inducible Treg polarization conditions before miR-124 transfection. IL-17A+ Th17 cells and FoxP3+ Treg induction was inhibited when miR-124 was overexpressed, whereas miR-124 promoted differentiation of IFN-γ+ Th1 cells (Supplementary Fig. 6 ).
miR-124 exerts a therapeutic effect in STAT3-expressing genetically engineered murine models
The limitation of evaluating therapeutic strategies in clonotypic models has been previously noted (32); we created a genetically engineered murine model that expresses STAT3 (11) . We injected newborn Ntv-a mice with RCAS-STAT3 and RCAS-PDGFB vectors to reproducibly and consistently obtain high-grade gliomas, with the defining histologic features of microvascular proliferation, necrosis, and invasion (Fig. 7A) and lacking miR-124 expression (Fig. 7B) . Similar to the findings in glioma patients, miR-124 expression in these induced gliomas was also markedly diminished. To determine whether treatment with miR-124 was also efficacious in this model system, we treated Ntv-a mice with miR-124, starting on day 21 after tumor induction. No behavioral or neurological abnormalities of the mice were noted during treatment. The median survival duration in the control group was 26 days. In mice treated with miR-124, the median survival duration was 39 days (P = 0.04) (Fig. 7C) . Necropsies of gliomabearing Ntv-a mice revealed that the miR-124-treated cohort had a lower incidence of highgrade gliomas, as determined by the study neuropathologist, on the basis of the characteristic features of necrosis and neovascular proliferation (Fig. 7D) 
evidence of demyelination, macrophage infiltration, or lymphocytic infiltration in the non-tumor bearing areas of the CNS that would indicate the induction of autoimmunity (data not shown).
Systemic administration of miR-124 resulted in lower p-STAT3 expression in the gliomas than in scrambled miRNA and untreated controls (Fig. 7E) .
DISCUSSION
To our knowledge, this is the first study to demonstrate that miRNA approaches can be exploited for immune therapeutic purposes against malignancies. A significant confounding factor in the translational implementation of miR-based approaches has been adequate delivery to the target tumor cells. To circumvent this, we selected a miRNA that could reverse tumormediated immune suppression-specifically, a key molecular hub, STAT3-resulting in immunological recognition and clearance of the malignancy. We have also provided a strategy for identifying potential miRNA immune therapeutics that may be applicable to other types of malignancies by sequentially: 1) screening for down-modulated miRNAs using tumor hypothesize that the GBM is negatively regulating the expression of miR-124 in the surrounding microglia/macrophage population.
When data from The Cancer Genome Atlas were used to compare miR-124 expression and survival in patients with GBM, no differences in patient outcome were identified; however, the miR-124 expression levels were negligible in these patients, and the marginal differences are probably attributable to the submitted specimens containing intervening miR-124-expressing infiltrating neurons. Given miR-124's role in neuronal development, we were not surprised to find that it was expressed in the normal CNS as assessed by in situ hybridization. miR-124 expression was lost across all grades and types of gliomas, suggesting not only that this loss is an early event in glioma initiation and development but also that miR-124 therapeutic approaches will be useful in a variety of gliomas. (44) and we found it can also target miR-21, which is regulated by STAT3 (19). miR-21 has been shown to be significantly elevated in GBMs and can regulate multiple genes associated with preventing glioma cell apoptosis (45) and enhancing migration and invasion (15) . miR-21 inhibition can inhibit the growth of GBM cells in vitro (18) and in vivo (16, 46) . Thus, a component of the observed in vivo therapeutic effect could be secondary to the modulation of miR-21 by miR-124. In summary, these findings provide proof-of-concept support for the systemic delivery of immune-modulatory miRNAs as a powerful and specific anticancer therapeutic modality. In the future, immune modulatory miRNAs could be used in combination and delivered in the context of nanoparticles, liposomes or exosomes or used to modify cellular vaccine strategies. Because the STAT3 pathway has been shown to mediate resistance to chemotherapeutics by modulating miR-17 (47), miR-124 may also have a therapeutic role in the setting of treatment failure.
Screening miRNA expression in tumors could ultimately lead to a personalized medicine approach. Ultimately, this novel immunotherapeutic approach has the potential to not only overcome immune quiescence and resistance but also to overcome the vexing issue of miRNA delivery by exploiting the immune system as an antitumor "Trojan horse." 
